Summer Sale

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Get 30% Off

Get 30% Off

Up to 30% off — ends 7 Aug

ONLY00h00m00s

Carlos A. Zarate Jr.

National Institute of Mental Health

United States

This profile is automatically generated from trusted academic sources.

Google Scholar

.

ORCID

.

LinkedIn

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI

Contact this professor

LinkedIn

Google Scholar

Research Interests

Pharmacology

60%

Pharmacotherapy

80%

Neuropharmacology

80%

Serotonin Research

40%

Major Depressive Disorder

30%

Drug Repurposing

30%

Neuroprotection

20%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles18

The Synergistic Effect of Bupropion-Dextromethorphan With Thyroid Supplementation in Treatment-Resistant Depression

Year:

2025

Relative effectiveness of antidepressant treatments in treatment-resistant depression: a systematic review and network meta-analysis of randomized controlled trials

Year:

2025

Esketamine in depression: putative biomarkers from clinical research

Year:

2024

Pharmacodynamic properties of lumateperone and its efficacy in acute bipolar depression: a mechanistic hypothesis based on data

Year:

2024

Carlos A. Zarate, Jr.: Using clinical translational neuroscience to develop the next generation of antidepressant treatments that act more rapidly and effectively

Year:

2024

Potential association between suicide risk, aggression, impulsivity, and the somatosensory system

Year:

2024

Clinical, behavioral, and electrophysiological profiles along a continuum of suicide risk: evidence from an implicit association task

Year:

2024

Antidepressant efficacy of cariprazine in bipolar disorder and the role of its pharmacodynamic properties: A hypothesis based on data

Year:

2023

κ-Opioid Receptor Plasma Levels Are Associated With Sex and Diagnosis of Major Depressive Disorder But Not Response to Ketamine

Year:

2023

Ketamine treatment for depression: a review

Year:

2022

Glutamate modulators and beyond: A neuroscience revolution in the making

Year:

2022

Lithium treatment of Bipolar disorder in adults: A systematic review of randomized trials and meta-analyses

Year:

2022

A wake-up call: Sleep physiology and related translational discrepancies in studies of rapid-acting antidepressants

Year:

2021

Commentary on the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder

Year:

2021

Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status

Year:

2021

Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?

Year:

2021

Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor

Year:

2021

Ketamine: a new chapter in antidepressant development

Year:

2020

Collaborators6

Tomi Rantamäki

University of Helsinki

FINLAND

Konstantinos Fountoulakis

Professor

Aristotle University of Thessaloniki

GREECE

Henrik Samuel Kohtala

University of Helsinki

FINLAND

Ioline Henter

National Institute of Mental Health

UNITED STATES

Mark Kvarta

National Institute of Mental Health

UNITED STATES

Rupert Lanzenberger

Prof. P.D. M.D.

Medical University of Vienna

AUSTRIA

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI